Business Context and Reporting Period
Company: Prima BioMed Ltd (also referred to as IMMUTEP Ltd in metadata, though the filing identifies Prima BioMed Ltd as the registrant).
Reporting Period: Fiscal year ended June 30, 2017.
Business Overview: Prima BioMed is an Australian biotechnology company focused on developing immunotherapeutic products for cancer treatment. The company's primary asset is the LAG-3 technology platform acquired via the purchase of Immutep SA in December 2014. Key product candidates include IMP321 (a recombinant protein in Phase II trials for breast cancer and melanoma), IMP701 (licensed to Novartis), IMP731 (licensed to GSK), and IMP761 (early-stage agonist antibody). The company has no approved products for commercial sale and relies on equity financing, grants, and milestone payments from partners.
Key Financial Metrics
| Metric (A$) | FY 2017 | FY 2016 |
|---|---|---|
| Revenue | $0 | $175,052 |
| Other Income | $4,221,534 | $1,853,869 |
| Net Loss | $(9,367,206) | $(62,015,184) |
| Loss Per Share (Basic/Diluted) | $(0.45) cents | $(3.08) cents |
| Cash and Cash Equivalents | $12,236,974 | $20,879,548 |
| Working Capital | $13,287,250 | $20,198,827 |
| Total Assets | $34,963,796 | $42,554,067 |
| Long-term Debt (Convertible Note) | $5,778,984 | $5,027,168 |
| Total Shareholders' Equity | $26,532,306 | $35,317,513 |
Note: Financial statements are prepared in Australian Dollars (A$) in accordance with IFRS.
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: Net loss decreased from A$62.0 million in FY2016 to A$9.4 million in FY2017. This improvement is primarily attributable to the absence of a one-time non-cash "Share Based Payment to strategic investor" expense of A$47.5 million recorded in FY2016 related to the Ridgeback Capital Investments transaction.
- Increased Other Income: Other income rose to A$4.2 million (from A$1.9 million), driven by a A$2.4 million increase in government grant income from Australian and French R&D tax incentive schemes.
- Reduced Administrative Expenses: Corporate administrative expenses fell by A$2.7 million to A$4.3 million, due to lower finance, legal, and consulting fees, as well as reduced employee share-based payment expenses.
- Cash Position: Cash and cash equivalents decreased by approximately A$8.6 million to A$12.2 million, reflecting net cash used in operating activities of A$8.5 million.
Guidance, Outlook, and Risks
Outlook and Capital Requirements: The company expects to continue incurring substantial losses as it advances clinical trials for IMP321 (AIPAC and TACTI-mel studies). Management anticipates that current cash resources, bolstered by a post-year-end capital raise of approximately A$5.3 million (completed July 2017), will fund operations for more than 12 months. However, the company will require additional funding to achieve long-term commercialization goals.
Key Risks and Contingencies:
- Going Concern: The company has a history of operating losses and negative cash flows. Continued operations depend on the ability to raise additional capital or secure strategic partnerships.
- Clinical Trial Uncertainty: Success depends on the safety and efficacy of product candidates in ongoing trials. Failure to achieve regulatory approval or positive trial results would prevent revenue generation.
- Passive Foreign Investment Company (PFIC): There is a substantial risk that the company is classified as a PFIC for U.S. tax purposes, which could result in adverse tax consequences for U.S. investors.
- Listing Compliance: The company has previously faced NASDAQ deficiency letters regarding minimum bid price rules. While compliance was regained, failure to maintain listing standards could result in delisting.
- Intellectual Property: The business relies heavily on patent protection for LAG-3 technology. Challenges to patents or inability to defend IP rights could materially harm the business.
Important Facts for Investor Verification
- Post-Year-End Capital Raise: Verify the completion and net proceeds of the registered direct offering of ADSs completed in July 2017 (approx. US$5.0 million gross).
- Cash Runway: Confirm the current cash balance and burn rate to assess the timeline for the next required capital raise.
- Clinical Trial Status: Monitor recruitment progress and interim data releases for the AIPAC (breast cancer) and TACTI-mel (melanoma) trials.
- Convertible Note Liability: Review the terms of the A$5.8 million convertible note liability issued to Ridgeback Capital Investments, including conversion triggers and maturity dates.
- Grant Income Sustainability: Assess the reliance on government R&D tax rebates (Australian and French) which significantly offset operating losses.